Suppr超能文献

普拉德-威利综合征中生长激素(GH)对生长激素释放六肽(GHRP-6)反应性的损害。

Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

作者信息

Grugni G, Guzzaloni G, Morabito F

机构信息

Division of Auxology, IRCCS S. Giuseppe Hospital, Istituto Auxologico Italiano Foundation, Verbania, Italy.

出版信息

J Endocrinol Invest. 2001 May;24(5):340-8. doi: 10.1007/BF03343871.

Abstract

The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, iv) or GHRH (1 microg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001. GHRH+PD: GHp: 15.1+/-2.4, p<0.009; AUC: 1249+/-248, p<0.003; nAUC: 918+/-230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005. GHRH+PD: GHp: 27.5+/-3.7, p<0.0001; AUC: 1873+/-251, p<0.0001; nAUC: 1692+/-219, p<0.0005). Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD. Interestingly, low IGF-I values were present in all PWS subjects. Furthermore, no patient with PWS showed normal GH response to the previously performed GH stimulation tests. As already reported, GH release after GHRP-6 or GHRH+PD was significantly lower in OB than in SN subjects. In conclusion, our data indicate that: 1) GH response to GHRP-6 is clearly impaired in PWS; 2) the blunted GH responses to the provocative stimuli in PWS are not an artifact of obesity; 3) short stature in PWS is caused by a complex dysfunction of the hypothalamo-pituitary structures.

摘要

本研究旨在评估合成六肽GHRP - 6在普拉德 - 威利综合征(PWS)中的生长激素释放活性。16例PWS患者(7例男性,9例女性,年龄12.7 - 38.3岁)、15例单纯性肥胖(OB)患者(7例男性,8例女性,年龄12.9 - 42.9岁)和8例身材矮小的正常儿童(SN;3例男性,5例女性,年龄10.2 - 14.3岁)在不同时间分别接受了2次测试,分别用GHRP - 6(1微克/千克,静脉注射)或生长激素释放激素(GHRH)(1微克/千克,静脉注射)+ PD(儿童或成人为60或120毫克,口服)进行刺激。此外,11例PWS患者和SN组中,此前已测定过至少2次刺激试验后的生长激素反应。生长激素分析采用平均峰值(GHp,微克/升)、曲线下面积(AUC,微克/升/小时)和曲线下净增加面积(nAUC,微克/升/小时)。在PWS组中,GHRP - 6(GHp:11.4±2.0;AUC:588±113;nAUC:483±108)和GHRH + PD(GHp:7.3±1.8;AUC:486±122;nAUC:371±250)刺激后的生长激素反应均显著低于OB组(GHRP - 6:GHp:25.7±3.2,p < 0.003;AUC:1833±305,p < 0.005;nAUC:1640±263,p < 0.0001。GHRH + PD:GHp:15.1±2.4,p < 0.009;AUC:1249±248,p < 0.003;nAUC:918±230,p < 0.006)和SN患者(GHRP - 6:GHp:39.1±3.1,p < 0.0001;AUC:2792±158,p < 0.0001;nAUC:2705±165,p < 0.00005。GHRH + PD:GHp:27.5±3.7,p < 0.0001;AUC:1873±251,p < 0.0001;nAUC:1692±219,p < 0.0005)。与对照组不同,PWS患者GHRP - 6刺激后的生长激素水平与GHRH + PD刺激后的水平无差异。有趣的是,所有PWS患者的胰岛素样生长因子 - I(IGF - I)值均较低。此外,没有PWS患者对之前进行的生长激素刺激试验表现出正常的生长激素反应。如之前报道的,OB患者GHRP - 6或GHRH + PD刺激后的生长激素释放显著低于SN患者。总之,我们的数据表明:1)PWS患者对GHRP - 6的生长激素反应明显受损;2)PWS患者对刺激性刺激的生长激素反应减弱并非肥胖所致;3)PWS患者身材矮小是由下丘脑 - 垂体结构的复杂功能障碍引起的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验